EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review

Miriam Hussein, Anders Bonde Jensen

Case Reports in Oncology · 24.05.2023 · 393-399

DOI: 10.1159/000529866 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 24.05.2023. Verfasst von Miriam Hussein und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy is widely used in cancer treatment, and the drug Capecitabine is often used in treatment of breast cancer and usually well-tolerated. Toxicity from Capecitabine typically involves hand-foot syndrome, fatigue, nausea, reduced appetite, and diarrhea, while severe liver toxicity is rarely seen. We present a case of a 63-year-old female with metastatic breast cancer, without liver metastasis, who developed a severe drug-induced liver injury (DILI) with critically elevated liver enzyme levels as reaction to Capecitabine treatment with seemingly no evident explanation as to why. The patient had a RUCAM score of 7 and a Naranjo score of 6 implying that this association between Capecitabine and the liver injury falls into the “probable” category. The patient recovered completely and was then successfully treated with other cytotoxic drugs without any sign of liver engagement. An in-depth literature search based on Pubmed database was performed to obtain information about Capecitabine, liver injury, and chemotherapy-associated acute hepatic toxicity. The following keywords were used: Capecitabine, chemotherapy, liver toxicity, and hepatic toxicity. Five studies were found showing some similarities to this case documenting hepatic injury after Capecitabine treatment including hepatic steatosis and moderately elevated liver enzymes. However, no studies were found reporting a severe DILI with highly elevated enzyme levels as immediate response to Capecitabine treatment. No reason could be identified as for why the patient developed an acute toxic liver reaction to Capecitabine. This case calls for more attention to the potential severe liver toxicity of an otherwise well-tolerated drug.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerCapecitabineDrug-induced liver injuryLiver toxicityRoussel Uclaf Causality Assessment Method

Autor:innen und Institutionen

  • Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Oncology and Institute of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.

Zitieren

APA

Hussein, M., & Jensen, A. B. (2023). Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review. Case Reports in Oncology, 393-399. https://doi.org/10.1159/000529866

Vancouver

Hussein M, Jensen AB. Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review. Case Reports in Oncology. 2023:393-399. doi:10.1159/000529866

BibTeX
@article{Hussein2023,
  author = {Hussein, Miriam and Jensen, Anders Bonde},
  title = {Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review},
  journal = {Case Reports in Oncology},
  year = {2023},
  pages = {393--399},
  doi = {10.1159/000529866}
}
Kostenlos starten →